Antibody-Free Protocol For Generation Of Highly Expandable, Non-Fibroadipogenic Mesodermal Precursors from Human Pluripotent Stem Cells For Treatment

Tech ID: 30170 / UC Case 2018-465-0

Summary

UCLA researchers in the Department of Orthopaedic Surgery have developed a novel method to generate mesodermal precursors from human pluripotent stem cells to treat chronic skeletal muscle atrophy and fibrosis.

Background

Cell based therapy has shown great promise in treating human muscle atrophy and fibrosis. Mesodermal progenitor cells provide a plentiful, precisely identified cell source that can be reproducibly induced to produce desired therapeutic cells. However, there is a shortage of suitable cell sources for the derivation of mesodermal progenitor cells, and cell sources greatly impact the differentiation and therapeutic efficiency of the drive progenitor cells. There is an unmet need to derive mesodermal progenitor cells of high quality and sufficient quantity.

Innovation

UCLA researchers in the Department of Orthopaedic Surgery have developed a novel method to derive mesodermal cells that will be sufficient for effective treatment of human muscle injury. A single step protocol is used to for generation of mesodermal cells from human pluripotent stem cells with 90% efficiency. Expansion of the derived cells resulted in a 104-fold increase in cell number within few weeks, without any additional cell sorting or isolation. When the derived mesodermal stem cells were injected in a murine muscle injury model, the numbers of diseased atrophic muscle myofibers significantly decreased.

Applications

  • Stem cell therapy 
  • Progenitor cell derivation 
  • Off-the-shelf cell therapy 
  • Cell-based drug screening 
  • Fibroadipogenic diseases of muscle, liver, lung, kidney, bone marrow and heart

Advantages

  • Cost-effective, omits the use of clinical grade antibodies or enzymes 
  • Cell source (human embryonic stem cells) plentiful 
  • Cell derivatives are phenotypically stable and uniform 
  • Cell derivatives are highly stable for cryopreservation
  • Cell derivatives are unable to differentiate into adipocytes or fibroblasts?

Related Materials

  • Devana SK, Kelley BV, McBride OJ, Kabir N, Jensen AR, Park SJ, Eliasberg CD, Dar A, Mosich GM, Kowalski TJ, Péault B, Petrigliano FA, SooHoo NF. Adipose-derived Human Perivascular Stem Cells May Improve Achilles Tendon Healing in Rats. Clin Orthop Relat Res. 2018 Oct;476(10):2091-2100.
  • Jensen AR, Kelley BV, Eliasberg C, Devana SK, Murray IR, McAllister DR, Péault B, Dar A, Petrigliano FA. PDGFRa+PDGFRß+ Fibroadipogenic progenitor cells contribute to fatty infiltration and fibrosis following massive rotator cuff tears in a murine model. J Shoulder Elbow Surg. 2018 Jul;27(7):1149-1161.

Patent Status

Patent Pending

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Petrigliano, Frank A.

Other Information

Keywords

human stem cell, cell therapy, muscle atrophy, fibrosis, mesodermal progenitor cells, embryonic stem cells, protocol

Categorized As